Johnson & Johnson Vision Receives FDA Approval for ACUVUE Abiliti™ Overnight Therapeutic Lenses for Myopia Control

Today, Johnson & Johnson Vision, a subsidiary of Johnson & Johnson, announced that the U.S. FDA has approved the market launch of its ACUVUE Abiliti therapeutic contact lens. Reportedly, this is the first orthokeratology contact lens approved by the U.S. FDA for myopia control.

Myopia is a progressive chronic eye disease. According to Nature Reviews Disease Primers, there are nearly 2 billion people with myopia worldwide, accounting for approximately 28.3% of the global population. It is projected that by 2050, nearly 50% of the world’s population will be affected by myopia. The prevalence of myopia is particularly high in urban areas of Southeast Asian countries, exceeding 80% among young people.

Myopia does not merely affect vision; studies have shown that children who develop myopia before the age of 12 are more likely to progress to high myopia, and their risk of subsequently developing sight-threatening conditions (such as macular degeneration) is significantly increased.

Orthokeratology Contact Lenses are individually designed based on the shape of the patient’s cornea. By gently reshaping the cornea, they alter its refractive power and have demonstrated safety and efficacy in controlling myopia progression across multiple clinical studies.

ACUVUE Abiliti is an orthokeratology contact lens worn by patients during sleep, eliminating the need for daytime wear. Clinical studies conducted in children with myopia demonstrated that ACUVUE Abiliti reduced axial elongation by 0.28 mm over a two-year period. Axial elongation is the primary driver of myopia progression in children.

Note: The original text has been abridged.

References:

[1] Johnson & Johnson Vision Announces FDA Approval ofACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management. RetrievedMay 12, 2021, from https://www.prnewswire.com/news-releases/johnson--johnson-vision-announces-fda-approval-of-acuvue-abiliti-overnight-therapeutic-lenses-for-myopia-management-301289377.html

[2] Baird et al., (2020). Myopia, Nature Reviews DiseasePrimers, https://doi.org/10.1038/s41572-020-00231-4

▽Follow [WuXi AppTecDe】WeChat Official Account